Are you Dr. Corn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 85 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Paul Corn, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor at Division of Cancer Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
University of ChicagoResidency, Internal Medicine, 1993 - 1996
Georgetown University School of MedicineClass of 1993
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2005 - 2026
OK State Medical License 2020 - 2021
PA State Medical License 2000 - 2004
MD State Medical License 1996 - 2000
Clinical Trials
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer Start of enrollment: 2008 Feb 01
- TKI258 in Castrate Resistant Prostate Cancer Start of enrollment: 2010 Apr 07
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- Body composition in recurrent prostate cancer and the role of steroidogenic genotype.Neha Venkatesh, Rebecca S Tidwell, Yao Yu, Ana Aparicio, Amado J Zurita
Endocrine-Related Cancer. 2024-12-01 - Polyploid cancer cells reveal signatures of chemotherapy resistance.Michael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, Mohamed Kamal, Radu Cadaneanu
Oncogene. 2024-11-22 - Polyploid cancer cells reveal signatures of chemotherapy resistance.James Hicks, Michael Schmidt, Amin Nahgdloo, Rishvanth Prabakar, Mohamed Kamal
Research Square. 2024-10-14
Press Mentions
Cancer Death Rates down but Racial Disparities Persist Among Black Men and WomenJanuary 12th, 2023
Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC SuccessMarch 14th, 2017
Study Identifies Possible New Combination Chemotherapy for Patients with Advanced Prostate CancerMay 30th, 2015
Grant Support
- Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2004–2007
- Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2003
